Download full text PDF

S.A. Zolotov Director for the Production and Development of Drugs and Active Pharmaceutical Substances LLC «AMEDART» (Moscow) E-mail: N.B. Demina Dr.Sc. (Pharm.), Professor, Department of Pharmaceutical Technology Institute of Pharmacy, Sechenov First Moscow State Medical University E-mail: A.S. Zolotova Ph.D. (Pharm.), Head of the Laboratory of Drug Technology LLC «Farm-Sintez Lab» (Moscow) E-mail:

The aim of the work was to study the physicochemical properties of darunavir ethanolate for the development of a scheme for the synthesis of a pharmaceutical substance and the creation of a domestic innovative dosage form. The following methods were used: differential scanning calorime-try, potentiometric titration, highly efficient liquid chromatography, capillary method for determining the melting point. The following parameters were determined: melting point, solubility in aqueous solutions and organic solvents, distribution coefficient, apparent distribution coefficient and dissociation constant. It is established that the substance is poorly soluble in aqueous solutions in the pH range from 1 to 12, soluble in a number of organic solvents. The distribution coefficient in the solvent system octanol 1 / phosphate buffer solution pH 7.0 was 292, the apparent distribution coefficient in the sol-vent system octanol / 0.1 N hydrochloric acid solution – 30.9. The dissociation constant was 2.02, the melting point is in the range from 74 to 78 °C. The obtained results were processed using Microsoft Office Excel 2016 software in MS Windows 7 environment. It was experimentally shown that the substance of darunavir ethanolate is lipophilic, the main site of its absorption by oral administration will be the intestine. To increase the effectiveness of the substance, the application of technologies aimed at increasing the solubility in aqueous media is promising. The article presents the results of the study of the physicochemical properties of the substance darunavir ethanolate antiretroviral action

dissociation constant
pharmaceutical development

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

  1. EMA/669488/2014 Corr. 1 Committee for Medicinal Products for Human Use (CHMP) Assessment report Rezolsta International non-proprietary name: darunavir/ cobicistat Procedure No. EMEA/H/C/002819/0000 September 2014.
  2. ICH Q8(R2). PHARMACEUTICAL DEVELOPMENT // Current Step 4 version.- August 2009.
  3. Dr. Fei Mao, Qingya Kong, Wei Ni, Xiang Xu, Dazheng Ling, Zhengyu Lu, Prof. Jian Li. Melting Point Distribution Analysis of Globally Approved and Discontinued Drugs: A Research for Improving the Chance of Success of Drug Design and Discovery // Chemistry Open. 2016 Aug; 5(4): 357–368.
  4. Reddy B.V., Jyothi G., Reddy B.S., Raman N.V., Reddy K.S., Rambabu C. Stability-indicating HPLC method for the determination of darunavir ethanolate // 2013 May-Jun; 51(5):471–476.
  5. Demina N.B. Biofarmaczevticheskaya klassifikaczionnaya sistema kak instrument razrabotki dizajna i tekhno¬logii lekarstvennoj formy` // Razrabotka i registracziya lekarstvenny`kh sredstv. 2017. № 2. S. 12–17.
  6. Chaves Ruela Corrеa J., D’Arcy D.M., dos Reis C.H., Nunes Salgado S.H.R. Darunavir: A Critical review of its properties, use and drug interactions // Pharmacology. 2012; 90:102–109.
  7. Reshenie Soveta Evrazijskoj e`konomicheskoj komissii ot 03.11.2016 N 78 (red. ot 14.06.2018) «O Pravilakh registraczii i e`kspertizy` lekarstvenny`kh sredstv dlya mediczinskogo primeneniya». Prilozhenie №14 s. 10
  8. Al`bert A. Izbiratel`naya toksichnost`. Fiziko-khimicheskie osnovy` terapii / Per. s angl. V 2 tomakh. T. 2. M.: Mediczina, 1989. 432 s.